Soluble arylsulfatase (EC 3.1.6.1) is present in the body fluids of man in the form of two isoenzymes, arylsulfatase A and B, which reportedly are useful biochemical markers for certain types of malignancy. However, rapid assay of the individual isoenzymes is extremely difficult; procedures based on differential inhibition or activation of the isoenzymes in a mixture yield only semiquantitative results. A feature of these isoenzymes is their inhibition by some common anions (notably phosphate) at physiologic concentrations. The isoenzymes can be separated by anionexchange chromatography, the B isoenzyme being eluted 
enzyme activityanion-exchange chromatography . isoenzymes -normal values . inherited disorders . Ag as a specific inhibitor Arylsulfatase enzymes (aryl-sulphate sulphohydrolase, EC 3.1.6.1) catalyze hydrolysis of phenolic sulfate esters to yield a phenolic compound and sulfate ion. Two major types of arylsulfatase enzymes occur in man, differing in physical and kinetic properties. The Type I enzyme, arylsulfatase C, is insoluble (thus seldom detectable in body fluids) and is located primarily in cell microsomes. This enzyme type shows a high activity toward such artificial substrates as p-nitrophenyl-, acetylphenyl-, and phenyl-sulfates. physiological substrate for sulfatase A (ASA) is cerebroside sulfate; a congenital defect of this enzyme is the cause of the metabolic disease metachromatic leukodystrophy, characterized by an accumulation of cerebroside sulfate in the body. Sulfatase B (ASB), which has been described as a N-acetylgalactosamine-4-sulfatase, is defective in the Maroteaux-Lamy syndrome.
A feature of the arylsulfatase Type II isoenzymes is their sensitivity to inhibition by various anionic species, including sulfite, sulfate, and phosphate.
In addition, arylsulfatase B is inhibited by chloride ion. The physical properties and physiologic roles of the arylsulfatase isoenzymes have been recently reviewed by Roy (1) and by Farooqui and Mandel (2, 3) .
The Type II arylsulfatase enzymes (ASA and ASB) have been proposed as potentially useful biochemical markers for several types of cancer. Increased sulfatase activity in dialyzed urine has been reported in myeloid leukemia; diseases of the bladder, testes, and uterus; and in cancer of the breast and of the prostatic gland (4) . Urinary ASB isoenzyme activity reportedly is increased in colorectal cancer (5) and ASA isoenzyme activity in malignant melanoma (6). Previously, Dzialosynski et al. (7) reported that nonspecific arylsulfatase activity (nitrocatechol sulfate used as the substrate) was increased relative to its activity in normal subjects for malignant tumors of the stomach, colon, breast, and skin. They reported (but no data were presented) that arylsulfatase activity in the sera from patients with malignancies did not differ distinctly from that found in healthy individuals. However, no precautions were taken to circumvent the effect of endogenous sulfatase inhibitors in serum; the determination of arylsulfatase enzymes in untreated serum is thus of questionable value (8) .
In addition, kinetic differentiation of the individual soluble arylsulfatase isoenzymes (ASB and ASA) by use of the artificial substrate nitrocatechol sulfate without prior physical separation is "problematic" (9). Baum et a!. (10) introduced a system of differential inhibitors and activators to discriminate between the isoenzymes present in human urine. This system has been utilized by almost all researchers investigating the roles of the individual isoenzymes in the body fluids of man. ASB is assayed in a medium containing barium acetate (5 mmol/liter), stated by Baum et al. to inhibit ASA but not to affect ASB. However, Agogbua and Wynn (11) report that ASB from human liver is considerably inhibited by barium ions, as is ASB from rat tissue (12) . The ASA retains considerable activity in the "ASBselective" reaction medium, and Baum et a!. used an empirical relationship to "correct" the kinetic data for the contribution of residual ASA activity (10, 12) . The assay medium for ASA contains 0.12 mmol of pyrophosphate per liter, said to inhibit ASB and to overcome the "anomalous kinetics" exhibited by ASA toward the nitrocatechol sulfate substrate (1, 10, 13). We have attempted to overcome some of the methodological difficulties associated with estimation of the activities of the individual arylsulfatase isoenzymes in the body fluids of man. We used a rapid ion-exchange chromatographic system to separate the isoenzymes and permit their unambiguous individual estimation. By this procedure, ASB is eluted free of endogenous anionic inhibitors and thus can be estimated without first dialyzing the sample. Dialysis, although effective in removing anionic interferents, is slow (and thus poorly suited to an enzyme screening approach) and requires a relatively large sample size. By use of our chromatographic procedure, we have demonstrated a high frequency of increased ASB activity in the sera of patients with colorectal cancer and malignant melanoma. By our procedure, ASA is co-eluted with endogenous anionic interferents. However, we have shown that lead may be used to sequester these anions in the column eluate, thus permitting determination of ASA in nondialyzed serum samples. In addition, we report the use of silver ion as a specific inhibitor of ASA in dialyzed urine, which permits estimation of the individual isoenzymes without the necessity of physically separating them.
Methods and Materials
Arylsulfatase Standards Reconstitute 8.5 mg of lyophilized salt-free sulfatase [from limpets (PateUa vulgata) ; properties similar to the Type II enzymes in man; Sigma Chemical Co., St. Louis, Mo. 63178; prod. no. S-8629 with 5.0 ml of dilute acetate buffer (50 mmol/liter, pH 5.6) or distilled water. Prepare a dilute stock solution of enzyme by adding 20 il of this solution to 1 ml of appropriate buffer. Prepare human urinary protein concentrate, containing arylsulfatase A, after the procedure of GniotSzulzycka (14, 15) . To a 100-ml aliquot of urine (5 to 10 #{176}C), add 1 ml of bovine serum albumin solution (20 g/liter in 50 mmol/liter acetate, pH 5.6). Add solid ammonium sulfate, with slow stirring, to give a final concentration of 3 mol/liter. Refrigerate the solution for at least 2 h before collecting the precipitate by centrifugation. Discard the supernatant solution, and redissolve the pellet in a minimal volume of the acetate buffer. Dialyze against dilute buffer and discard any insoluble material.
Human Serum and Urine Specimens
Abnormal specimens (obtained through the National Cancer Institute Sample Repository, administered by Litton Bionetics, Inc., Frederick Cancer Research Center, Frederick, Md. 21701) were stored frozen at -70 #{176}C until thawed for analysis. Urine samples were filtered to remove cell debris, and aliquots were dialyzed against acetate buffer (10 mmol/liter, pH 5.6). Pharmacia Fine Chemicals, Uppsala, Sweden). Packed in such a manner, the columns have a void volume sufficient to retain a 0.5-ml sample when initially applied. The fibrous material was used in some of the earlier development work; however, the spherical ion-exchanger has better liquid flow rates and sample recovery and thus is preferred for use in separating the arylsulfatase isoenzymes. For high-performance liquid-chromatographic separation we used a stationary phase of Glycophase DEAE-CPG, 5-to 10-tim particles (Corning, Biological Products Dept., Medfield, Mass. 02052), packed in a 3.2 mm (i.d.) by 25 cm column. Sample volume was 72 il, column pressure 110 MPa (1600 psi).
Albumin Standards

Procedures
Optical measurements.
All optical measurements were made with a miniature Centrifugal Fast Analyzer system (16, 17 Creatinine was determined by an adaptation of the kinetic procedure described by Ward et al. (20) .
Albumin estimation.
Albumin was estimated by an adaptation of the procedure of Savory et al. 
Results
Chromatographic
Separation of Arylsulfatase lsoenzymes
At pH values exceeding the isoelectric pH (p1) of a macromolecule, the molecule assumes a net negative charge and thus will be retained on an anion-exchange resin. Human placental ASB is reported to have three bands upon isoelectric focusing, with p1 values of 7.6, 7.9, and 8. at pH values of 6.8 to 7.6 by use of a NaCl concentration gradient (ASA is eluted in the salt-containing eluate). Figure 1 illustrates the effect of pH on the separation and analytical recovery of the two soluble isoenzymes of limpet arylsulfatase on fibrous diethylaminoethylcellulose. Dilute sulfatase (0.5 ml) in the appropriate starting buffer is placed on the column (in Figure 1 , the displaced volume is fraction 1), and the column is eluted with 0.5-mi aliquots of appropriate buffer. Two isoenzymes are clearly separated by anion-exchange chromatography.
Effect of Eluent pH
However, a greater activity is measured in the eluate fractions separated at pH 5.5 compared to pH 7.5 (all fractions are subsequently analyzed in 0.5 mol/liter of acetate buffer, pH 5.6). The total enzyme activity recovered (fibrous cellulose) was 61% at pH 5.5, and only 33% at pH 7.5.
In addition to an effect on the recovery of the isoenzymes of limpet arylsulfatase from DEAE-cellulose, the pH of the eluent fractions had an apparent effect upon the storage stability of the enzymes. Figure 2 shows the stability of dilute limpet sulfatase (a mixture of isoenzymes) in buffers of pH 5.5 (50 mmol/liter acetate) and pH 7.5 (50 mmol/liter Tris acetate) to incubation at 37 #{176}C. Clearly, storage stability is improved at pH 5.5. The addition of nonspecific protein enhances storage stability slightly at pH 7.5, but has a negligible effect at pH 5.5. Figure 3 shows the concentrations of anions inhibiting arylsulfatase (Type II) in the body fluids of man and superimposes these normal range data upon the data 
Effect of Endogenous Anions in the Sample
D.C., 1961
that demonstrate the effect of sulfate and phosphate ions on the activity of purified human ASA (as reported by Gniot-Szulzycka in ref. 13 ). Obviously, phosphate ion is the most potent endogenous arylsulfatase inhibitor. Figure 1 shows the elution pattern for a sample containing 1 mmoi of phosphate ion per liter, which does not elute until concentrated salt is added to the eluate. The anions chloride and sulfate exhibit similar behavior on the exchange medium (acetate form). Thus, ASB (unretained fraction) may be rapidly separated by anion exchange from both ASA and endogenous anion interferents, without the necessity of sample pretreatment. A urine specimen was fractionated by anion-exchange chromatography, with and without prior dialysis of the sample. The unretained (ASB) fractions were assayed and found to have the following activities (fig nitrocatechol/ml per hour at 37 #{176}C): 14.3 (dialyzed urine) and 14.6 (untreated urine). Rinderknecht et al. (8) acidified serum to pH 5.6 to 5.8 and applied the sample to a column packed with Dowex 1 (X-8, OH-form) resin. Treatment by this technique, it was claimed, completely eliminated inhibition in the column eluate and yielded slightly greater activities than obtained from dialyzed samples. Analysis of the serum eluate according to the selective inhibition system described by Baum et a!. (10) caused Rinderknecht et a!. to conclude that isoenzyme ASB is the preponderant isoenzyme in norma! serum. From the discussion above, it is apparent that the anionic protein ASA, as well as the anionic inhibitors, were retained on the column and not eluted by their procedure, thus influencing their conclusions.
Effect of Protein
The apparent activity of dilute, purified limpet sulfatase is dramatically affected by the presence of small amounts of nonspecific protein, as shown in Figure 4 . with and without bovine serum albumin (a similar effect was noted for limpet ASB). This phenomenon is apparently not a serious factor for human arylsulfatase; norma! urine (low total protein) exhibited only an 8% increase in apparent ASA activity upon supplementing the sample with bovine serum albumin, 1 g/liter.
Albumin affects the analytical recovery of sulfatase isoenzymes from DEAE-cellulose, as illustrated in Figure 6 . Bovine serum albumin (BSA) is an anionic protein, coeluting with ASA in the salt-containing eluent. Allowing for the apparent enhancement of ASA activity in albumin-containing medium, the recovery as total arylsulfatase is 15% greater (fibrous cellulose, pH 7.5) for a sample containing albumin than for one without. Again, this effect may be significant when low-protein samples (such as normal urine) are chromatographed.
At pH 5.5 on DEAE-Sephacel (-4 ml bed volume), 12 mg of bovine serum albumin is retained on the column and subsequently desorbed by salt-elution. Thus, treatment of the minicolumn with 0.5 ml of a 20 g/liter BSA solution essentially saturates the column. Phosphate ion and ASA were found to be more strongly bound under these conditions than is BSA, and are thus retained on the albumin-treated column. At pH 5.5 on DEAE-Sephacel, the analytical recovery of individual limpet isoenzymes (corrected for activity enhancement due to protein) are: ASB, 53% (untreated column) vs. 93% (BSA-treated column); and ASA, 88% (untreated) vs. 99% (BSA-treated). Protein-treated DEAE-Sephacel therefore is used to obtain essentially quantitative recovery of arylsulfatase isoenzymes in urine samples. Serum samples contain sufficient albumin to be quantitatively recovered from untreated minicolumns.
Effect of Lead Ion
Harinath and Robins (24, 26) reported that the addition of lead ion (2 to 3 mmol/liter) to nondialyzed arylsulfatase enzyme fractions appeared to overcome any endogenous inhibition, as indicated by obtaining enzymatic activity approximately equal to that of a dialyzed preparation.
We therefore investigated the utility of lead treatment of column-chromatographic eluents containing ASA, as a rapid means of estimating this isoenzyme in eluate fractions without sample dialysis.
Using chromatographica!ly separated isoenzymes, we found that 2.5 mmol of lead nitrate per liter neither activated nor inhibited limpet arylsulfatase.
Lead ion forms stable, sparingly soluble complexes with the sulfatase inhibitors phosphate and sulfate ion. Figure 7 illustrates the effect of lead ion on total limpet arylsulfatase activity in the presence of 2.5 mmol of phosphate ion per liter, with and without added BSA (the data have been corrected for the effect of BSA on apparent limpet sulfatase activity). When lead is added to the phosphate-containing buffer without BSA, a precipitate is formed, which must be removed by centrifugation; no such precipitate is formed when BSA is One detriment to the procedure of adding lead ion to protein-containing column eluates is the apparent catalytic effect of lead on the denaturation/degradation of protein under the strongly basic pH conditions used to develop the nitrocatechol (NC) chromophore. This phenomenon is illustrated in Figure 8 for a mixture of BSA, lead, and KOH. The mixture rapidly discolors, which interferes with the measurement of absorbance at 510 nm (absorption maximum for NC), and even more so at shorter wavelengths. This phenomenon can lead to gross overestimation of arylsulfatase activity. The rate of protein degradation is proportional to the concentration of both lead ion ( Figure 9 ) and serum protein (Figure 10) . The lead-protein interaction may be largely circumvented by adding sthichiometri excess (relative to added lead ion) of ethylenediaminetetraacetic acid (EDTA) to the KOH used to develop the NC chromophore, as shown in Figure 11 . Under alkaline conditions, EDTA forms a strong complex with free lead ion. Singh et a!. (27) have also advocated use of EDTA in the analysis of ASA in serum to prevent the formation of a heavy precipitate (presumably calcium hydroxide or carbonate) when concentrated base is added. Third, and of particular interest, is the effect of silver ion on the activity of the separated isoenzymes. Addition of silver ion (0.24-mmol/liter sample concentration, 0.12-mmol/liter incubation concentration) negligibly affects ASB in dialyzed human serum, while totally inhibiting the activity of dialyzed human urinary ASA. Harinath and Robins (24) reported that AgNO3 (0.25 mmol/liter) produced a 96% inhibition of human brain ASA, while stimulating the activity of the ASB isoenzyme. Silver ion, like lead, forms highly stable complexes with the arylsulfatase inhibitors phosphate and sulfate, and the sample must be dialyzed to determine the true effect of Ag+ on arylsulfatase isoenzymes. Farooqui and Mandel (2) attribute the inhibitory effect 
Effect of Diverse Ions
Assay of Chromatographicaiiy Separated Arylsulfatase lsoenzymes in the Body Fluids of Man
Posey and Morgan (30) reported that arylsulfatase enzymes may be released into the bloodstream and subsequently cleared by the kidneys as a result of increased tumor volume, increased turnover of the malignant cell population, direct shedding of malignant cells into the urine, increased lysosomal lability, or some combination of these. Morgan et al. (5) reported that ASB activity in dialyzed 24-h urine specimens was above normal in 71% of patients with colorectal cancer whom they examined.
In contrast, ASB activity in tumor tissue was increased in only 24% of the colorectal cancer patients examined. They reported that ASB activity in the urine did increase as the disease progressed.
In Table 2 , we report the activity of arylsulfatase isoenzymes in the chromatographically separated body fluids of colorectal cancer patients (urine specimens were chromatographed on bovine serum albumintreated DEAE-Sephacel).
Increased arylsulfatase isoenzyme activity becomes significantly more common in colorectal cancer patient serum when the effect of endogenous anionic inhibitors is obviated by chromatographic separation (for ASB) or treatment with lead (for ASA). This finding is in contrast to most serum studies, where the effect of these inhibitors was not realized (4, 7). Also included in Table 2 are the serum activities of a battery of hepatobiliary enzymes (19, 31, 32) : -y-glutamyltransferase (GGT), leucine aminopeptidase (LAP), and alkaline phosphatase (AP). The frequency with which hepatobiliary enzyme activities in the serum samples are above normal suggests considerable metastasis to the liver in some patients (31) (32) (33) . Table 3 reports enzyme activities in serum from malignant melanoma patients. The work of Posey et al. (6) suggests that activities of ASA and nonspecific arylsulfatase are increased in the urine of patients with this disease. For these patients, arylsulfatase enzymes, as well as the hepatobiliary enzymes, often are found to be above normal. Table 4 summarizes our findings for potential enzyme biomarkers in the body fluids of patients with colorectal cancer or malignant melanoma. For colorectal cancer patients, we noted a higher frequency of increased ASB (71.4% vs. 15.4%) and ASA (42.9% vs. 21.4%) activity for serum samples than for urine samples. Arylsulfatase B has a greater frequency of elevated activity in these sera than does ASA or the hepatobiliary enzymes. Of the hepatobiliary enzymes, y-glutamyltransferase is the most frequently increased. However, this enzyme shows above-normal activity in several hepatic diseases, and its activity is increased in situations that lead to microsomal enzyme induction by drugs such as alcohol (31-33).
As indicated previously, an increased arylsulfatase isoenzyme activity was found less commonly in the urine specimens. The samples were not identified as being 24-h urine specimens, and there is a very striking diurnal variation in the urinary excretion of arylsulfatase enzymes (5, 34) . Specimens used to establish the normal range values given in Table 2 were collected between 08:00 and 12:00 hours, when excretion of arylsulfatase is greatest. If patients' specimens were collected at other time intervals, this would decrease the apparent prevalence of above-normal arylsulfatase isoenzyme activity. Urinary creatinine concentrations were determined (20) , and patients' arylsulfatase activities were computed in terms of urinary creatinine. This only marginally affected the frequency of abnormal urinary arylsulfatase.
The overall reproducibility of our assay protocol, including the separation procedure, was assessed by triplicate analysis of a dialyzed normal urine specimen. The following activities were found (micrograms of nitrocatechol per milliliter per hour at 37 #{176}C): ASB, 10.53 ± 0.26 (CV = 2.5%); ASA, 15.76 ± 0.38 (CV = 2.4%).
Our normal range estimates for the arylsulfatase isoenzymes are compared to those values reported in the literature in Tables 5 (ASB) urine volume of 1400 ml is assumed, in order to express those estimates of urinary arylsulfatase enzymes reported in the literature in terms of a common unit (micrograms of nitrocatechol per milliliter per hour at 37 #{176}C). The normal-range values of the other authors were established by using the protocol of Baum et al.
(10), whereas our own values were calculated from the initial rate (first 30 mm) of the reaction, when reaction velocity is greatest for both the isoenzymes (9).
In Table 7 , we compare activity estimates by our procedure of chromatographic separation of isoenzymes with the analysis of isoenzymes in mixture, using (a) the differential inhibition effect of silver ion, and (b) the computational procedure of Baum et a!. (10) . The difference between the activities as estimated by the initial rate approach, with and without added silver ion, is a measure of the residual activity of ASA in the ASBselective reagent system. ASA retains considerable activity in the ASB-selective reagent, at least for the first 30 mm of incubation. In general, estimates of ASB activity agree well for the initial rate data for chromatographically separated ASB and for ASB in mixture, with Ag used to suppress ASA activity. The procedure of Baum attempts to correct the data for the maximum ASA contribution to the activity of ASB measured with ASB-selective reagent, and yields much lower estimates of ASB activity than do the other two procedures. This is one reason why our normal range estimates for ASB (Table 5 ) appear higher than those established by the protocol of Baum et al. If the empirical correction factor is appropriate, then there should be no difference in ASB activity estimated with or without added silver ion by the Baum procedure. The effect of added silver ion on the estimation of sulfatase activity in the isoenzyme-selective reagent systems is illustrated in Figure  12 . The contribution of ASB to activity measured with ASA-selective reagent is minimal. 
Continuous Separation and Assay of Arylsuifatase lsoenzymes
Discontinuous chromatography on anion-exchange minicolumns as described above is relatively slow, and activity determination of dilute eluate fractions by use of nitrocatechol sulfate substrate often requires long incubation times. We became interested in the possibility of continuous chromatography of sulfatase isoenzymes with on-line column effluent monitoring. As an alternative to the use of nitrocatechol sulfate as a substrate, we first investigated the use of 4-methylumbelliferone sulfate (MUS). The human arylsulfatase enzymes have a lower affinity for MUS than for nitrocatechol sulfate and its specific rate of hydrolysis is lower (typically 5 to 10% of the specific rate for NC sulfate substrate).
However, assay of the liberated reaction product, 4-methylumbelliferone (4-MU), is much more sensitive than nitrocatechol by a factor of two to three orders of magnitude (35) and, in contrast to nitrocatechol, 4-MU can be monitored directly in the reaction medium without adding reaction-quenching chemicals. Figure 13 illustrates the relative fluorescence spectra of fluorogenic MUS and the product. In terms of absolute fluorescence intensity, our MUS substrate (Sigma Chemical Co.) had a response (relative to 4-MU) of only 0.002% at 440 nm (the emission maximum for 4-MU). Another attractive feature of the use of MUS as a substrate is that it yields a linear rate of hydrolysis for ASA without the "anomalous kinetics" noted for NC sulfate substrate (36) . We also hoped that by use of a continuous salt gradient we even highly dilute purified enzyme gave a slight background response coincident with the elution volume of ASB. When the system was used with human urine, the endogenous fluorescence was simply overwhelming (Figure 15 ). The urine illustrated in Figure 15 , from a colorectal cancer patient, had endogenous fluorescent compounds which coeluted with both ASB and ASA. The corresponding eluent fractions of raw urine (no substrate) were collected and found to have both excitation and emission spectra which overlapped those for methylumbelliferone.
As shown in Figure 15 , the endogenous fluorescent compounds could be removed largely by dialysis; thus, in contrast to spectrophotometric determination of column eluate fractions, even the analysis of ASB in urine would require exhaustive dialysis before the detector response would be specific for arylsulfatase activity. These difficulties caused us to investigate the possibilities of using nitrocatechol sulfate substrate for photometric on-line monitoring of sulfatase activity eluted from the chromatographic system. The problems anticipated were reduced sensitivity (relative to fluo- is likely to give a change in absorbance at 510 nm upon addition of the base, the detector response is highly selective for sulfatase activity. An integrating time constant for the signal between reference and sample beams makes the system nonresponsive to slugs of nonspecific chromophores eluted by the chromatograph. Figure 17 shows the detector response to chromatographically separated sulfatases in native (i.e., nondialyzed) normal urine supplemented with purified limpet sulfatase. Also shown is the response of the system to native urine in the absence of sulfatase substrate; in contrast to Figure 15 , no false peaks were obtained. If serum samples are to be examined, then addition of lead ion to the nonspecific reagent may permit continuous chromatographic separation and assay of both soluble arylsulfatase isoenzymes without prior sample treatment. Because protein, lead, and base are only in contact for a few seconds before reaching the detector, no protein degradation will occur to obscure the estimation of enzyme activity.
In summary, the isoenzymes of arysulfatase are easily separated by ion-exchange chromatography.
We have discussed conditions that result in essentially quantitative recovery of the enzymes from the chromatographic medium.
We have shown that silver ion is a much more selective inhibitor for discriminating between sulfatase isoenzymes in mixture than are the isoenzyme-selective reagent systems of Baum et al. (10) . Silver ion, by its ability to inhibit ASA, may be used to quantitate arylsulfatase isoenzymes in dialyzed urine samples.
We demonstrate that arylsulfatase activity, especially that of ASB isoenzyme, is frequently above normal in the sera of patients with colorectal cancer and malignant melanoma. The enzymes may thus be suitable biochemical markers that may be used as a noninvasive measure of malignant cell activity (39, 40) . Although arylsulfatase activities are generally greater in urine samples than in serum samples (Tables 5 and 6 ), variable urinary excretion of enzyme (34) and greatly increased concentrations of endogenous inhibitors ( Figure  1 ) are noted. In serum samples, the presence of endogenous inhibitors may be obviated by the addition of lead nitrate (2.5 mmol/liter).
Serum enzyme activities may be directly compared, whereas the activities in urine are best referenced to total 24-h volume or creatinine excretion. 
